Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.62 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | LTK | P29376 | 1/20 | 0.62 |
| ▸ | GRK5 | P34947 | 1/20 | 0.62 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.62 |
| ▸ | CDK8 | P49336 | 1/20 | 0.62 |
| ▸ | PRKX | P51817 | 1/20 | 0.62 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.62 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.62 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.62 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.62 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016818 | 1.00 | CHEK1 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL30834838 | 0.85 | CA12 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL1476316 | 0.85 | CA12 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL32689426 | 0.77 | CHEK1 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL29441946 | 0.77 | CHEK1 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL30873095 | 0.77 | CA12 (0.73) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL2208975 | 0.77 | CHEK1 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL3988311 | 0.77 | CA12 (0.73) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL3984666 | 0.77 | RET (1.00) | CHEK1DAPK3MAP4K4RETPIM1 | |
| SCHEMBL1666180 | 0.77 | CHEK1 (0.62) | CHEK1DAPK3MAP4K4RETPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103694-A1 | HDAC INHIBITOR, AND PREPARATION AND USE THEREOF | 赛岚(杭州)生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-118019735-A | Arylsulfonyl compounds as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
| US-7671221-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671221-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671221-B2 | Modulators of ATP-Binding Cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-02 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| WO-2009006315-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR TREATING CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | CHEK1 1363/4885DAPK3 2657/4885MAP4K4 2953/4885 |
| US-20080009524-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | CHEK1 4693/4885DAPK3 4344/4885MAP4K4 4714/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | CHEK1 125/4885DAPK3 247/4885MAP4K4 469/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | CHEK1 2740/4885DAPK3 3216/4885MAP4K4 227/4885 |
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | CHEK1 4647/4885DAPK3 4519/4885MAP4K4 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.